ALPMF (Astellas Pharma) Valuation Rank


ALPMF Astellas Pharma Inc ALPMF
73 GF Score
Price $14.20
GF Value $14.67
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Astellas Pharma Valuation Rank Related Terms

ALPMF
73GF Score
Astellas Pharma Inc ALPMF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $14.20 is trading 3.2% below its estimated GF Value™ of $14.67. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Valuation Rank:
  • GF Value™: $14.67 vs. price of $14.20 (3.2% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score

Get the complete analysis for ALPMF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.20
Price
$14.67
GF Value